Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA) Krapf R; Hulter HNClin J Am Soc Nephrol 2009[Feb]; 4 (2): 470-80This review summarizes the evidence for a hypertensinogenic effect of Erythropoietin (Epo) in normal human subjects and predialysis, hemodialysis, and continuous ambulatory peritoneal dialysis (CAPD) patients. The possible mechanisms of Epo-induced hypertension are examined with in vivo animal and in vitro data, as well as pathophysiological human studies in both normal subjects and CKD patients. The evidence for a hypertensinogenic effect of erythropoiesis-stimulating agents (ESAs) in normal subjects, predialysis CKD, hemodialysis, and CAPD patients is compelling. Epo increases BP directly and notably independently of its erythropoietic effect and its effect on blood rheology. The potential for the development of future agents that might act as specific stimulators of erythropoiesis, devoid of direct hemodynamic side effects is underscored.|*Peritoneal Dialysis, Continuous Ambulatory[MESH]|*Renal Dialysis[MESH]|Anemia/*drug therapy/etiology[MESH]|Animals[MESH]|Arteries/*drug effects/physiopathology[MESH]|Blood Pressure/*drug effects[MESH]|Chronic Disease[MESH]|Erythropoietin/*adverse effects[MESH]|Evidence-Based Medicine[MESH]|Hematinics/*adverse effects[MESH]|Humans[MESH]|Hypertension/*chemically induced/physiopathology[MESH]|Kidney Diseases/complications/*therapy[MESH]|Risk Assessment[MESH] |
